Need professional-grade analysis? Visit stockanalysis.com
$19.93B
113.27
1,981
1.22%
Walvax BioTech (300142) trades on SHE in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY12.46, down 2.20% from the previous close.
Over the past year, 300142 has traded between a low of CNY9.85 and a high of CNY14.48. The stock has gained 22.1% over this period. It is currently 14.0% below its 52-week high.
Walvax BioTech has a market capitalization of $19.93B, with a price-to-earnings ratio of 113.27 and a dividend yield of 1.22%.
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Side-by-side comparison against top Healthcare peers.